AlzeCure Pharma AB (FRA:AC6) Institutional Ownership: 0.01% (As of Jul. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:AC6 AlzeCure Pharma AB FRA:AC6
33 GF Score
Price €0.51
! 1 Warning Sign
View Full Analysis

What is AlzeCure Pharma AB Institutional Ownership?

AlzeCure Pharma AB FRA:AC6 -3.41% 33 Institutional Ownership is 0.01% as of Jul. 20, 2026. GuruFocus rates FRA:AC6 with a GF Score™ of 33/100. The stock has 1 warning sign investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, AlzeCure Pharma AB's institutional ownership is 0.01%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, AlzeCure Pharma AB's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, AlzeCure Pharma AB's Float Percentage Of Total Shares Outstanding is 0.00%.

AlzeCure Pharma AB Institutional Ownership Historical Data

* Premium members only.

The historical data trend for AlzeCure Pharma AB's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AlzeCure Pharma AB Institutional Ownership Chart

AlzeCure Pharma AB Historical Data

The historical data trend for AlzeCure Pharma AB can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.01 0.01
FRA:AC6
33GF Score
AlzeCure Pharma AB FRA:AC6
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AlzeCure Pharma AB Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.01% mean?
AlzeCure Pharma AB (FRA:AC6) has a Institutional Ownership of 0.01% as of Jul. 20, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on AlzeCure Pharma AB and its competitors.
Is AlzeCure Pharma AB's Institutional Ownership too high?
AlzeCure Pharma AB's current Institutional Ownership is 0.01%. Overall, AlzeCure Pharma AB has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does AlzeCure Pharma AB's Institutional Ownership compare to VRTX and REGN?
AlzeCure Pharma AB's Institutional Ownership of 0.01% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on AlzeCure Pharma AB and its competitors. AlzeCure Pharma AB's current Institutional Ownership is 0.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AlzeCure Pharma AB stock overvalued right now?
AlzeCure Pharma AB (FRA:AC6) has a current Institutional Ownership of 0.01%. The current Institutional Ownership is 0.01%. AlzeCure Pharma AB's overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For AlzeCure Pharma AB (FRA:AC6), the current Institutional Ownership is 0.01% as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AlzeCure Pharma AB Business Description

Other Exchanges ALZCUR:Sweden
Address Halsovagen 7, Huddinge, SWE, SE 141 57
AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in drug research with a primary focus on Alzheimer's disease. The company develops several drugs within its three research platforms, NeuroRestore, Alzstatin, and Painless. The company's drug candidates include: ACD440, which is in the clinical development phase for the treatment of neuropathic pain, ACD856, ACD857, and ACD680 for the treatment of Alzheimer's disease, and ACD137 for the treatment of severe pain in conditions such as osteoarthritis.
33GF Score

Get the complete analysis for FRA:AC6

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.51
Price